CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure Is Acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart Failure Sodium-Glucose Co-Transporter 2 Inhibitors and Insights from Biomarker Measurement in Heart Failure Patients

Editorial17 Nov 201

JOURNAL:Circulation. Article Link

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

Martinez FA, Serenelli M, Nicolau JC et al. Keywords: dapagliflozin; HFrEF; efficacy; safety

FULL TEXT PDF